December 8, 2025Blood

IVIG successfully halts a recurrent hyperhaemolysis syndrome in a young patient with sickle cell crisis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case report shows rapid hemoglobin increase in a sickle cell patient with recurrent hyperhaemolysis syndrome, suggesting IVIG’s potential benefits.

Improved hemoglobin from 4.8 to 7.3 mg/dl after IVIG treatment, highlighting its effectiveness.
Ferritin levels increased to 33K, indicating severe hemolysis alongside reticulocyte spike from 11% to 27%.
Treatment involved IVIG and steroids after halting potentially harmful blood transfusions.
Maladaptive immune response may underlie recurrent hyperhaemolysis syndrome, needing alternative therapies.

Rajesh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case report shows rapid hemoglobin increase in a sickle cell patient with recurrent hyperhaemolysis syndrome, suggesting IVIG’s potential benefits.